MagForce AG supports brain cancer patient event of University Hospital Münster in the run-up to World Brain Tumor Day 2016

Berlin, Germany and Nevada, USA, May 24, 2016 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that the Company is participating in the event for brain cancer patients and their relatives which will be hosted by the Brain Tumor Center of University Hospital Münster on May 27, 2016 in the run-up to World Brain Tumor Day.

The event includes a guided tour and a workshop to inform the persons concerned about the important and supporting concomitant therapies like art- and sports therapy to psychooncologically support the patients as well as about treatment options for brain cancer. The event will take place at the Pablo Picasso Museum of Graphic Art in Münster, Germany, on Friday 27, 2016, from 15:00 to 17:00 CET. MagForce will be available for questions regarding its NanoTherm™ therapy and will be represented by a booth in the foyer of the museum.

The University Hospital Münster was the second clinic to install a NanoActivator® device, following the Charité University Hospital in Berlin. Prof. Dr. med. Walter Stummer, Director of the Neurosurgery Department at the University Hospital Münster and Chair of the UKM Brain Tumor Centre, has initiated the NanoTherm™ therapy for treatment of brain tumors patients beginning of 2015 in addition of being the lead investigator of the Magforce post-marketing clinical trial.

About the World Brain Tumor Day

This commemoration day was initialised by the Deutsche Hirntumorhilfe e.V. (German Brain Tumour Association) in 2000 with the aim of directing public attention towards this little-known disease. Because brain tumours occur rather seldom in comparison to other cancers, they are little-noticed by the public. The World Brain Tumor Day calls public attention to the situation of brain tumour patients and appeals for solidarity with patients and their dependants. It is also a reminder directed to the responsible persons in the fields of politics and economy to assume their social responsibility. Active support of research and an increased interdisciplinary collaboration are the ways to develop new therapies and improve the chances of healing. Until that, it is essential to campaign together to advance the quality of life of patients, to give hope and show solidarity – it is essential to send a signal.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device...
company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com.

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Contact:
Barbara von Frankenberg
Vice President Communications & Investor Relations
MagForce AG
Phone +49 30 308 380-77
E-mail: bfrankenberg@magforce.com